Advertisement

Central European Journal of Medicine

, Volume 1, Issue 2, pp 136–147 | Cite as

The relationship between features of metabolic syndrome and blood adipocytokine concentrations in the morbid obese patients during dynamic weight loss

  • Joanna Jankiewicz-Wika
  • Krzysztof Kołomecki
  • Jacek Cywiński
  • Katarzyna Piestrzeniewicz
  • Henryk Stępień
  • Jan Komorowski
Research Article

Abstract

Bariatric surgery is the most effective method to achieve weight loss in obese subjects.

The aim of this study was to evaluate some adipocytokines and insulin, as well as parameters of metabolic syndrome of the obese patients, for three and six months after vertical banded gastroplasty, in the time of dynamic weight loss.

Seven males and two females aged 28 to 49 years, with long lasting simple obesity and the presence of metabolic syndrome, were studied. After surgical treatment the values of the body mass index, waist circumference, systolic and diastolic blood pressure, total cholesterol, LDL cholesterol, triglycerides, and blood concentrations of leptin decreased significantly.

Before surgical operation of all obese patients no statistically significant correlations between studied parameters were noted. Three and six months later a lot of correlations between studied parameters appeared.

In conclusion, (a) vertical-banded gastroplasty is a valuable method in treatment of obese subjects, leading to a significant decrease in body weight and improvement in some parameters of metabolic syndrome in a few months after surgery, (b) adipocytokines, together with an unknown gastric factor, may be key factors in the control of some features of the metabolic syndrome.

Keywords

Obesity metabolic syndrome adiponectin leptin resistin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    D.E. Cummings and M.W. Schwartz: “Genetics and pathophysiology of human obesity”, Ann. Rev. Med., Vol. 54, (2003), pp. 453–471.PubMedCrossRefGoogle Scholar
  2. [2]
    B.E. Wisse and M.W. Schwartz: “The skinny of neurotrophins”, Nature Neurosci., Vol. 6, (2003), pp. 655–656.PubMedCrossRefGoogle Scholar
  3. [3]
    S.M. Grundy: “Obesity, metabolic syndrome, and cardiovascular disease”, J. Clin. Endocrinol. Metabol., Vol. 89, (2004), pp. 2595–2600.CrossRefGoogle Scholar
  4. [4]
    C.C. Carr and J.D. Brunzell: “Abdominal obesity and dyslipidemia in the metabolic syndrome: Importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk”, J. Clin. Endocrinol. Metabol., Vol. 89, (2004), pp. 2601–2607.CrossRefGoogle Scholar
  5. [5]
    M. Lafontan and M. Berlan: “Do regional differences in adipocyte biology provide new pathopysiological insights?”, Trends Pharmacol. Sci., Vol. 24, (2003), pp. 276–283.PubMedCrossRefGoogle Scholar
  6. [6]
    K.G. Alberti and P.Z. Zimmet: “Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabetes Med., Vol. 15, (1998), pp. 539–553.CrossRefGoogle Scholar
  7. [7]
    National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report on the National Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)”, JAMA, Vol. 285 (2001), pp. 2486–2497.CrossRefGoogle Scholar
  8. [8]
    W. Fujimoto, S. Abbate, S. Kahn, J. Hokanson and J. Brunzell: “The visceral adiposity syndrome in Japanese-American men”, Obes. Res., Vol. 2, (1994), pp. 364–371.PubMedGoogle Scholar
  9. [9]
    N. Ruderman, D. Chisholm, X. Pi-Sunyer and S. Schneider: “The metabolically obese, normal-weight individuals revisited”, Diabetes, Vol. 47, (1998), pp. 699–713.PubMedGoogle Scholar
  10. [10]
    N. Barzilai, L. She, B.Q. Liu, P. Vuguin, P. Cohen, J. Wang and L. Rosetti,:, “Surgical removal of visceral fat reverses hepatic insulin resistance”, Diabetes, Vol. 48, (1999), pp. 94–98.PubMedGoogle Scholar
  11. [11]
    J. Harvey and M.L.J. Ashford: “Leptin in CNS: Much for than a satiety signal”, Neuropharmacology, Vol. 44, (2003), pp. 845–854.PubMedCrossRefGoogle Scholar
  12. [12]
    J. Komorowski, J. Jankiewicz-Wika and H. Stępień: “Effects of Gn-RH, TRH, and CRF administration on plasma leptin levels ln lean and obese women”, Neuropeptides, Vol. 34, (2000), pp. 89–97.PubMedCrossRefGoogle Scholar
  13. [13]
    S. Ten and N. MacLaren: “Insulin resistance in children”, J. Clin. Endocrinol. Metabol., Vol. 89, (2004), pp. 2526–2539.CrossRefGoogle Scholar
  14. [14]
    G.K. Shetty, P.A. Economides, E.S. Horton, Ch.S. Mantzoros and A. Veves: “Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes”, Diabetes Care, Vol. 27, (2004), pp. 2450–2457.PubMedGoogle Scholar
  15. [15]
    Y. Arita, S. Kihara, N. Ouchi, M. Takahashi, K. Maeda, J. Miyagawa, K. Hotta, I. Shimomura, T. Nakamura, K. Miyaoka, H. Kuriyama, M. Nishida, S. Yamashita, K. Okubo, K. Matsubara, M. Muraguchi, Y. Ohmoto, T. Funahashi and Y. Matsuzawa: “Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity”, Biochem. Biophys. Res. Commun., Vol. 257, (1999), pp. 79–83.PubMedCrossRefGoogle Scholar
  16. [16]
    Y. Yamamoto, Y. Hirose, I. Saito, M. Tomita, M. Taniyama, K. Matsubara, Y. Okazaki, T. Ishi, K. Nishikai and T. Saruta: “Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-choesterol, independent of body mass index, in the Japanese population”, Clin. Sci. (Lond.), Vol. 103, (2002), pp. 132–147.Google Scholar
  17. [17]
    M. Matsubara, S. Maruka and S. Katayose: “Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women”, Eur. J. Endocrinol., Vol. 147, (2002), pp. 173–180.PubMedCrossRefGoogle Scholar
  18. [18]
    C.M. Steppan, S.T. Bailey, S. Bhat, E.J. Brown, R.R. Banerjee, C.M. Wright, H.M. Patel, R.S. Ahima and M.A. Lazar: “The hormone resistin links obesity to diabetes”, Nature, Vol. 409, (2001), pp. 307–312.PubMedCrossRefGoogle Scholar
  19. [19]
    C.M. Steppan and M.A. Lazar: “Resistin and obesity-associated insulin resistance”, Trends Endocrinol. Metab., Vol. 13, (2002), pp. 18–23.PubMedCrossRefGoogle Scholar
  20. [20]
    R. Ohmori, Y. Momiyama, R. Kato, H. Toniguchi, M. Ogura, M. Ayori, H. Nakamura and F. Ohsuzu: “Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease”, J. Am. Coll. Cardiol., Vol. 45, (2005), pp. 379–380.CrossRefGoogle Scholar
  21. [21]
    R.E. Brolin: “Bariatric surgery and long-term control of morbid obesity”, JAMA, Vol. 288, (2002), pp. 2793–2796.PubMedCrossRefGoogle Scholar
  22. [22]
    E.C. Mun, G.L Blackburn and J.B. Matthews: “Current status of medical and surgical therapy for obesity”, Gastroenterology, Vol. 120, (2001), pp. 669–681.PubMedCrossRefGoogle Scholar
  23. [23]
    D.E. Cummings, J. Overduin and K.E. Foster-Schubert: “Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution”, J. Clin. Endocrinol. Metabol, Vol. 89, (2002), pp. 2608–2615.CrossRefGoogle Scholar
  24. [24]
    G.A. Bray and L.A. Tartaglia: “Medicinal strategies in the treatment of obesity”, Nature, Vol. 404, (2000), pp. 672–677.PubMedGoogle Scholar
  25. [25]
    K.M. Mc Tigue, R. Harris, B. Hemphill, L. Lux, S. Sutton, A.J. Bunton and K.N. Lohr: “Screening and interventions for obesity in adults: summary of the evidence for the US Prevention Task Force”, Ann. Intern. Med., Vol. 139, (2003), pp. 933–949.Google Scholar
  26. [26]
    W.J. Pories, M.S. Swanson, K.G. Mac Donald, S.B. Long, P.G. Morris, B.M. Brown, H.A. Barakat, R.A. de Ramon, D. Israel and J.M. Dolezal: “Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus”, Ann. Surg., Vol. 222, (1995), pp. 339–352.PubMedGoogle Scholar
  27. [27]
    L. Sjostrom, A-K. Lindroos, M. Peltonen, J. Torgrson, C. Bouchard, B. Carlsoon, S. Dahlgren, B. Larsen, K. Narbro, C.D. Siostrom, M. Sullivan and H. Wedel: “Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery”. N. Engl. J. Med., Vol. 351, (2004), pp. 2683–2693.PubMedCrossRefGoogle Scholar
  28. [28]
    H. Buchwald, Y. Avidor, E. Braunwald, M.D. Jensen, W. Pories, K. Fahrbach and K. Schoelles: “Bariatric surgery”, JAMA, Vol. 292, (2004), pp. 1724–1737.PubMedCrossRefGoogle Scholar
  29. [29]
    N. Kubota, Y. Terauchi, T. Yamauchi, T. Kubota, M. Moroi, J. Matsui, K. Eto, T. Yamashita, J. Kamon, H. Satoh, W. Yano, P. Frogeul, R. Nagai, S. Kimura, T. Kadowaki and T. Noda: “Disruption of adiponectin causes insulin resistance and neointimal formation”, J. Biol. Chem., Vol. 277, (2002), pp. 25863–25866.PubMedCrossRefGoogle Scholar
  30. [30]
    T. Yamauchi, J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M.L. Reitman, K. Kagechika, Y. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel and T. Kadowaki: “The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity”, Nat. Med, Vol. 7, (2001), pp. 941–946.PubMedCrossRefGoogle Scholar
  31. [31]
    M. Blucher, M.D. Michael, O.D. Peroni, K. Ueki, N. Carter, B.B. Kahn and C.R. Kahn: “Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance”, Dev. Cell., Vol. 3, (2002), pp. 25–38.CrossRefGoogle Scholar
  32. [32]
    N. Stefan, B. Vozarova, T. Funahashi, Y. Matsuzawa, C. Weyer, S. Lindsay, J.F. Yongren, P.J. Havel, R.E. Pratley, C. Bogardus and P.A. Tataranni: “Plasma adiponectin concentrations in association with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans”, Diabetes, Vol. 51, (2002), pp. 1884–1888.PubMedGoogle Scholar
  33. [33]
    R.S. Lindsay, T. Funahashi, L.R. Hanson, Y. Matsuzawa, S. Tanaka, P.A. Tataranni, W.C. Knowler and J. Krakoff: “Adiponectin and development of type 2 diabetes in the Pima Indian population”, Lancet, Vol. 360, (2002), pp. 57–58.PubMedCrossRefGoogle Scholar
  34. [34]
    T. Yokota, K. Oritani, I. Takahashi, J. Ishikawa, A. Matsuyama, N. Ouchi, S. Kichara, T. Funahashi, A.J. Tenner, Y. Tomiyama and Y. Matsuzawa: “Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages”, Blood, Vol. 96, (2000), pp. 1723–1732.PubMedGoogle Scholar
  35. [35]
    N. Ouchi, S. Kichara, Y. Arilsa, K. Maeda, H. Kuriyama, Y. Okamoto, K. Hotta, M. Nishida, M. Takahashi, T. Nakamura, S. Yamashita, T. Funahashi and Y. Matsuzawa: “Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin”, Circulation, Vol. 100, (1999), pp. 2473–2476.PubMedGoogle Scholar
  36. [36]
    N. Ouchi, S. Kihara, Y. Ariata, M. Nishida, A. Matsuyama and Y Okamoto: “Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages”, Circulation, Vol. 103, (2001), pp. 1057–1063.PubMedGoogle Scholar
  37. [37]
    M. Matsubara, S. Maruka and S. Katayose: “Inverse relationship between plasma adiponectin and leptin concentrations in normal weight and obese women. Eur. J. Endocrinol., Vol. 147, (2002), pp. 173–180.PubMedCrossRefGoogle Scholar
  38. [38]
    C. Weyer, T. Funahashi, S. Tanaka, K. Hotta, Y. Matsuzawa, R.E. Pratley and P.A. Tataranni: “Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia”, J. Clin. Endocrinol. Metabol., Vol. 86, (2001), pp. 1930–1935.CrossRefGoogle Scholar
  39. [39]
    J.G. Yu, A.L. Javorschi Havener, Y.T. Kruszynska, R.A. Norman, M. Sinha and J.M. Olefsky: “The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetes subjects”, Diabetes, Vol. 51, (2002), pp. 2968–2974.PubMedGoogle Scholar
  40. [40]
    N. Satoh, Y. Ogawa, T. Usui, T. Tagami, S. Kono, H. Uesugi, H. Sugiyama, A. Sugawara, K. Yamada, A. Shimatsu, H. Kuzuya and K. Nakao: “Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect”, Diabetes Care, Vol. 26, (2003), pp. 2493–2499.PubMedGoogle Scholar
  41. [41]
    I.A. Harsch, C. Koebnick, H. Wallaschofski, S.P. Schahin, E.G. Hahn, J.H. Ficker, T. Lohmann and P.C. Konturek: “Resistin levels in patients with obstructive sleep apnea syndrome-the link to subclinical inflammation?”, Med. Sci. Monitor, Vol. 10, (2004), pp. CR510–515.Google Scholar
  42. [42]
    N. Siswal, A.K Singh, B. Aruna, S. Mukhopadhyay, S. Ghosh and N.Z. Ehtesham: “Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway”, Biochem. Biophys. Res. Commun., Vol. 334, (2005), pp. 1092–1101.CrossRefGoogle Scholar
  43. [43]
    G.H. Ballantyne, A. Gumbs and I.M. Modlin: “Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin”, Obes Surg, Vol. 15, (2005), pp. 692–699.PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Joanna Jankiewicz-Wika
    • 1
  • Krzysztof Kołomecki
    • 2
  • Jacek Cywiński
    • 2
  • Katarzyna Piestrzeniewicz
    • 3
  • Henryk Stępień
    • 1
  • Jan Komorowski
    • 1
  1. 1.Department of EndocrinologyMedical University of ŁódźPoland
  2. 2.Department of General SurgeryMinistry of the Interior HospitalŁódźPoland
  3. 3.Department of CardiologyMedical University of ŁódźŁódźPoland

Personalised recommendations